Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease

US8097605B2 · kind B2 · utility

Assignee

• MEDA PHARMA GMBH & CO. KG · DE

Inventors

• Joachim Maus · Mühlheim, DE
• Peter Cnota · Bad Homburg vor der Höhe, DE
• Istvan Szelenyi · Arnstorf, DE
• Beatrix Fyrnys · Zwingenberg, DE

Key dates

• Filing date: Feb 3, 2009
• Grant date: Jan 17, 2012
• Expiry date: Feb 3, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.